A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy

Clinical Nephrology

Volumn 52, Issue 2, 1999, Pages 67-75

  Boumpas, D T ^a,b   Tassiulas, I O ^a   Fleisher, T A ^a   Vaughan, E ^a   Piscitelli, S ^a   Kim, Y ^a   Pucino, F ^a   Balow, J E ^a   Austin, H A ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Lymphopenia; Pharmacokinetics; Regeneration

Indexed keywords

ALKYLATING AGENT; ANTIBIOTIC AGENT; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN; FLUDARABINE; IMMUNOGLOBULIN; PREDNISONE; PURINE NUCLEOSIDE DERIVATIVE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PLASMA FLOW; LYMPHOCYTE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PROTEINURIA; SINUSITIS; T LYMPHOCYTE;

ADULT; ALKYLATING AGENTS; ANTI-INFLAMMATORY AGENTS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; PILOT PROJECTS; PREDNISONE; PROTEINURIA; RENAL PLASMA FLOW, EFFECTIVE; SINUSITIS; VIDARABINE;

EID: 0032791636     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Austin HA, Antonovych TT, MacKay K, Boumpas DT, Balow JE 1992 Membranous nephropathy. Ann Intern Med 116: 672-682
2. Austin HA, Falk RJ 1999 Treatment of idiopathic membranous nephropathy. In: Brenner BM, Brady HR, Wilcox CS (eds) Current Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's the Kidney. Saunders, Philadelphia, pp 189-198
3. Cattran DC, Pei Y, Greenwood C 1992 Predicting progression in membranous glomerulonephritis. Nephrol Dial Transplant 7 (Suppl 1): 48-52
4. Cheson B 1995 Infections and immunosuppressive complications of purine analogue therapy. J Clin Oncol 13: 2431-2448
5. Cheson BD, Keating MJ, Plunket W 1997 Nucleoside Analogs is Cancer Therapy. Marcel Decker, New York
6. Conolly K, Roubinian JR, Wofsy D 1992 Development of murine lupus in CD4-depleted NZB/NZW mice sustained inhibition of residual CD4+ T cells is required to suppress autoimmunity. J Immunol 149: 3083-3088
7. Couser WG 1993 Pathogenesis of glomerulonephritis. Kidney Int 44: S19-26
8. Davis JC, Fessler BJ, Tassiulas IO, Yarboro CH, McInnes I, Lee J, Pillemer S, Klippel HJ, Boumpas DT 1998 High-dose versus low-dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis. J Rheumatol 15: 1694-1703
9. Farquhar MG, Saito A, Kerjaschki D, Orlando RA 1995 The Heymann nephritis antigenic complex: Megalin (gp330) and RAP. J Am Soc Nephrol 6: 35-47
10. Floege J, Kriz W, Schulze M, Susani M, Kerjaschki D, Monney A, Couser WG, Kock KM 1995 Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy. J Clin Invest 96: 2809-2819
11. Glassock RJ, Cohen AH, Adler SG 1996 Primary glomerular disease. In: Brenner BM (ed) The Kidney (5th ed, vol 2). Saunders, Philadelphia
12. Kerjaschki D, Neale TJ 1996 Molecular mechanisms of glomerular injury in rat experimental membranous nephropathy (Heymann Nephritis). J Am Soc Nephrol 7: 518-2526
13. Koyama A, Fujsaki M, Kobayashi M, Igarashi M, Narita M 1991 A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 40: 453-460
14. Levey AS, Greene T, Schluchter MD, Clean PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WK, Siebert C, Hall PM, Steffes MW 1993 Glomerular filtration rate measurements in clinical trials. J Am Soc Nephrol 4: 1159-1171
15. Mackall C, Fleisher T, Brown M, Andrick MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM 1995 Age, thymopoiesis and CD4 T+ lymphocyte regeneration after intensive chemotherapy. N Engl J Med 332: 143-149
16. Mackall CL, Hakim FT, Gress RE 1997 T cell regeneration: All repertoires are not created equal. Immunol Today 18: 245-251
17. Mallick NP, Short CD, Monas J 1983 Clinical membranous nephropathy. Nephron 34: 209-219
18. Noel LH, Zanetti M, Droz D, Barbanel C 1979 Long-term prognosis of idiopathic membranous glomerulonephritis. Study of 116 untreated patients. Am J Med 66: 82-90
19. Nussenblatt RB, de Smet MD, Rubin B, Freidlin V, Whitcup SM, Davis J, Herman D, Bloom JN, Sran PK, Whitcher S, Palestine A, Austin H 1993 A masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin. Am J Ophthalmol 115: 583-591
20. Ordonez JD, Hiatt RA, Killebrew KJ, Fireman BH 1993 The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 44: 638-642
21. Penny MJ, Boyd RA, Hall BM 1998 Permanent CD8+ T cell depletion prevents proteinuria in active Heyman nephritis. J Exp Med 188: 1775-1784
22. Ponticelli C, Zucchelli P, Passerini P, Cagnoli L, Cesana B, Pozzi C, Pasquali S, Imbasciati E, Grassi C, Redaelli B, Sadelli M, Locatelli F 1989 A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy. N Engl J Med 320: 8-13
23. Salant DJ, Quigg RJ, Cybulsky AV 1989 Heymann nephritis: Mechanisms of renal injury. Kidney Int 35: 976-984
24. Tassialas IO, Davis JC Jr, Fessler BJ, Hama N, Fleisher TA, Austin HA, Boumpas DT 1997 Fludarabine in non-malignant disorders. In: Cheson BD, MJ Keating, Plunket W (eds) Nucleoside Analogs is Cancer Therapy. Marcel Decker, New York, pp 383-414